Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology

Recipharm, a leading contract development and manufacturing organisation (CDMO) is pleased to announce an exclusive licence and collaboration agreement with Medspray and Resyca, to develop soft mist nasal delivery devices for single and combination drug products.

This collaboration extends the successful partnership between Recipharm and Medspray which resulted in the joint venture, Resyca; a company which is developing soft mist inhalers utilising Medspray’s nozzle technology to achieve high lung doses and less degradation of biological active pharmaceutical ingredients.

Under the terms of the agreement, Resyca gains exclusive rights to Medspray’s proprietary spray nozzle technology for use in nasal devices and combination drug products. This collaboration enables Resyca to provide all aspects of turnkey solutions for both oral and nasal inhalation, leveraging soft mist technology.

Han van Egmond, CEO at Medspray said: “Extending this agreement involves combining our cutting-edge nasal technology with Resyca’s product development capabilities. This collaboration with Resyca will enable us to bring innovative solutions to the market that will redefine the landscape of nasal drug delivery.”

It is anticipated that the enhanced collaboration will result in breakthroughs in the nasal delivery of fragile biological formulations, such as mRNA vaccines for pandemic applications.

“We are thrilled to enter into this extended strategic partnership with Medspray,” said Remko Beimers, CEO at Resyca. “This move aligns perfectly with our mission to pioneer advancements in aerosol drug delivery systems. The exclusive licence from Medspray will significantly strengthen our position in the market, allowing us to bring innovative and effective soft mist nasal delivery devices to patients worldwide together with our pharma customers.”

Recipharm, as a key player in the pharmaceutical CDMO industry, recognises the potential impact of this collaboration on the advancement of nasal drug delivery. “We are proud to be associated with Medspray and Resyca in this landmark licensing agreement,” said Chris Hirst, President, Advanced Delivery Systems at Recipharm. “As a CDMO committed to driving innovation, we look forward to supporting both companies in bringing their pioneering soft mist nasal delivery devices to the market to improve patient experience and expand what is possible via the nasal delivery route.”